Skip to content

Study · Non-randomized trial · 2023

23 results

Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT.

Agarwal S, Shiau S, Kamanda-Kosseh M, Bucovsky M, Kil N, Lappe JM, Stubby J, Recker RR, Guo XE, Shane E, Cohen A

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research24 Nov 2022Cited by 19 (Europe PMC)

PMID36335582 (opens in a new tab)DOI10.1002/jbmr.4739 (opens in a new tab)PepBankPUB-36335582
Publisher pagePubMedAsk about this study
Jump to 23 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study23

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, tibial trabecular number increased after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, tibial trabecular number increased after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial trabecular number
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Measurements

    Change
    3.3%
    After teriparatide

    Source sentences

    Summary
    After teriparatide, significant improvements were seen in tibial trabecular number (3.3%, p = 0.01), cortical area and thickness (both 2.7%, p < 0.001), and radial trabecular microarchitecture (number: 6.8%, thickness: 2.2%, separation: -5.1%, all p < 0.02).
    2 context sentences
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, tibial cortical area increased after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, tibial cortical area increased after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical area
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Measurements

    Change
    2.7%
    After teriparatide

    Source sentences

    Summary
    After teriparatide, significant improvements were seen in tibial trabecular number (3.3%, p = 0.01), cortical area and thickness (both 2.7%, p < 0.001), and radial trabecular microarchitecture (number: 6.8%, thickness: 2.2%, separation: -5.1%, all p < 0.02).
    2 context sentences
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, tibial cortical thickness increased after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, tibial cortical thickness increased after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTibial cortical thickness
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Measurements

    Change
    2.7%
    After teriparatide

    Source sentences

    Summary
    After teriparatide, significant improvements were seen in tibial trabecular number (3.3%, p = 0.01), cortical area and thickness (both 2.7%, p < 0.001), and radial trabecular microarchitecture (number: 6.8%, thickness: 2.2%, separation: -5.1%, all p < 0.02).
    3 context sentences
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.
  4. 04HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, radial trabecular number increased after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, radial trabecular number increased after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadial trabecular number
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Measurements

    Change
    6.8%
    After teriparatide

    Source sentences

    Summary
    After teriparatide, significant improvements were seen in tibial trabecular number (3.3%, p = 0.01), cortical area and thickness (both 2.7%, p < 0.001), and radial trabecular microarchitecture (number: 6.8%, thickness: 2.2%, separation: -5.1%, all p < 0.02).
    3 context sentences
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.
  5. 05HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, radial trabecular thickness increased after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, radial trabecular thickness increased after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadial trabecular thickness
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Measurements

    Change
    2.2%
    After teriparatide

    Source sentences

    Summary
    After teriparatide, significant improvements were seen in tibial trabecular number (3.3%, p = 0.01), cortical area and thickness (both 2.7%, p < 0.001), and radial trabecular microarchitecture (number: 6.8%, thickness: 2.2%, separation: -5.1%, all p < 0.02).
    3 context sentences
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.
  6. 06HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, radial trabecular separation decreased after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, radial trabecular separation decreased after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseRadial trabecular separation
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Measurements

    Change
    −5.1%
    After teriparatide

    Source sentences

    Summary
    After teriparatide, significant improvements were seen in tibial trabecular number (3.3%, p = 0.01), cortical area and thickness (both 2.7%, p < 0.001), and radial trabecular microarchitecture (number: 6.8%, thickness: 2.2%, separation: -5.1%, all p < 0.02).
    3 context sentences
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.
  7. 07HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, cortical porosity increased after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, cortical porosity increased after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCortical porosity
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Despite increases in cortical porosity and decreases in cortical density, whole-bone stiffness and failure load increased at both sites.
    3 context sentences
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
  8. 08HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, cortical density decreased after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, cortical density decreased after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseCortical density
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Despite increases in cortical porosity and decreases in cortical density, whole-bone stiffness and failure load increased at both sites.
    3 context sentences
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
  9. 09HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, whole-bone stiffness increased at tibia and radius after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, bone stiffness increased at tibia and radius after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseWhole-bone stiffness at tibia and radius
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Despite increases in cortical porosity and decreases in cortical density, whole-bone stiffness and failure load increased at both sites.
    3 context sentences
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.
  10. 10HumanNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, failure load increased at tibia and radius after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, failure load increased at tibia and radius after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFailure load at tibia and radius
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 mcg daily · 24 monthsAs given in this study (human).

    Source sentences

    Summary
    Despite increases in cortical porosity and decreases in cortical density, whole-bone stiffness and failure load increased at both sites.
    2 context sentences
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.

Studies that did not test the peptide alone13

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 11HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, tibial total vBMD increased during denosumab after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, total tibial bone density increased during denosumab after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePost-denosumab tibial total vBMD
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Total vBMD change
    3.5%
    Tibia after denosumab

    Source sentences

    Summary
    After denosumab, increases in total (3.5%, p < 0.001 and 3.3%, p = 0.02) and cortical vBMD (1.7% and 3.2%; both p < 0.01), and failure load (1.1% and 3.6%; both p < 0.05) were seen at tibia and radius, respectively.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  2. 12HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, radial total vBMD increased during denosumab after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, total radial bone density increased during denosumab after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePost-denosumab radial total vBMD
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Total vBMD change
    3.3%
    Radius after denosumab

    Source sentences

    Summary
    After denosumab, increases in total (3.5%, p < 0.001 and 3.3%, p = 0.02) and cortical vBMD (1.7% and 3.2%; both p < 0.01), and failure load (1.1% and 3.6%; both p < 0.05) were seen at tibia and radius, respectively.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  3. 13HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, tibial cortical vBMD increased during denosumab after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, cortical tibial bone density increased during denosumab after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePost-denosumab tibial cortical vBMD
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Cortical vBMD change
    1.7%
    Tibia after denosumab

    Source sentences

    Summary
    After denosumab, increases in total (3.5%, p < 0.001 and 3.3%, p = 0.02) and cortical vBMD (1.7% and 3.2%; both p < 0.01), and failure load (1.1% and 3.6%; both p < 0.05) were seen at tibia and radius, respectively.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  4. 14HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, radial cortical vBMD increased during denosumab after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, cortical radial bone density increased during denosumab after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePost-denosumab radial cortical vBMD
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Cortical vBMD change
    3.2%
    Radius after denosumab

    Source sentences

    Summary
    After denosumab, increases in total (3.5%, p < 0.001 and 3.3%, p = 0.02) and cortical vBMD (1.7% and 3.2%; both p < 0.01), and failure load (1.1% and 3.6%; both p < 0.05) were seen at tibia and radius, respectively.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  5. 15HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, tibial trabecular density increased during denosumab after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, tibial trabecular density increased during denosumab after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePost-denosumab tibial trabecular density
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Trabecular density change
    3.5%
    Tibia after denosumab

    Source sentences

    Summary
    Trabecular density (3.5%, p < 0.001) and number (2.4%, p = 0.03) increased at the tibia, while thickness (3.0%, p = 0.02) increased at the radius.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  6. 16HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, tibial trabecular number increased during denosumab after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, tibial trabecular number increased during denosumab after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePost-denosumab tibial trabecular number
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Trabecular number change
    2.4%
    Tibia after denosumab

    Source sentences

    Summary
    Trabecular density (3.5%, p < 0.001) and number (2.4%, p = 0.03) increased at the tibia, while thickness (3.0%, p = 0.02) increased at the radius.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  7. 17HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, radial trabecular thickness increased during denosumab after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, radial trabecular thickness increased during denosumab after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePost-denosumab radial trabecular thickness
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Trabecular thickness change
    3%
    Radius after denosumab

    Source sentences

    Summary
    Trabecular density (3.5%, p < 0.001) and number (2.4%, p = 0.03) increased at the tibia, while thickness (3.0%, p = 0.02) increased at the radius.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Primary outcomes were percentage change in vBMD, microstructure, and stiffness after teriparatide and after denosumab.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  8. 18HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, sequential teriparatide and denosumab increased total vBMD at tibia and radius.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, sequential teriparatide and denosumab increased total bone density at tibia and radius.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSequential treatment total vBMD
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 48 months of sequential treatment, significant increases in total vBMD (tibia: p < 0.001; radius: p = 0.01), trabecular microstructure (p < 0.05), cortical thickness (tibia: p < 0.001; radius: p = 0.02), and whole bone strength (p < 0.02) were seen at both sites.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Changes after sequential teriparatide and denosumab were secondary outcomes.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  9. 19HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, trabecular microstructure improved at both sites after sequential teriparatide and denosumab.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, trabecular microstructure improved at both sites after sequential teriparatide and denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSequential treatment trabecular microstructure
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 48 months of sequential treatment, significant increases in total vBMD (tibia: p < 0.001; radius: p = 0.01), trabecular microstructure (p < 0.05), cortical thickness (tibia: p < 0.001; radius: p = 0.02), and whole bone strength (p < 0.02) were seen at both sites.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Changes after sequential teriparatide and denosumab were secondary outcomes.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  10. 20HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, cortical thickness increased at both sites after sequential teriparatide and denosumab.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, cortical thickness increased at both sites after sequential teriparatide and denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSequential treatment cortical thickness
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 48 months of sequential treatment, significant increases in total vBMD (tibia: p < 0.001; radius: p = 0.01), trabecular microstructure (p < 0.05), cortical thickness (tibia: p < 0.001; radius: p = 0.02), and whole bone strength (p < 0.02) were seen at both sites.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Changes after sequential teriparatide and denosumab were secondary outcomes.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  11. 21HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, whole-bone strength increased at both sites after sequential teriparatide and denosumab.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, whole-bone strength increased at both sites after sequential teriparatide and denosumab.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSequential treatment whole-bone strength
    Study

    n: not reported in source

    Analysis
    Secondary
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    After 48 months of sequential treatment, significant increases in total vBMD (tibia: p < 0.001; radius: p = 0.01), trabecular microstructure (p < 0.05), cortical thickness (tibia: p < 0.001; radius: p = 0.02), and whole bone strength (p < 0.02) were seen at both sites.
    4 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.
    Summary · context
    Changes after sequential teriparatide and denosumab were secondary outcomes.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  12. 22HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, tibial failure load increased during denosumab after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, tibial failure load increased during denosumab after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePost-denosumab tibial failure load
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Failure load change
    1.1%
    Tibia after denosumab

    Source sentences

    Summary
    After denosumab, increases in total (3.5%, p < 0.001 and 3.3%, p = 0.02) and cortical vBMD (1.7% and 3.2%; both p < 0.01), and failure load (1.1% and 3.6%; both p < 0.05) were seen at tibia and radius, respectively.
    3 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

  13. 23HumanNot a test of Teriparatide (PTH 1-34) aloneNon-randomized trialEfficacy outcome

    In premenopausal women with idiopathic osteoporosis, radial failure load increased during denosumab after teriparatide.

    In plain wordsIn premenopausal women with idiopathic osteoporosis, radial failure load increased during denosumab after teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePost-denosumab radial failure load
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Measurements

    Failure load change
    3.6%
    Radius after denosumab

    Source sentences

    Summary
    After denosumab, increases in total (3.5%, p < 0.001 and 3.3%, p = 0.02) and cortical vBMD (1.7% and 3.2%; both p < 0.01), and failure load (1.1% and 3.6%; both p < 0.05) were seen at tibia and radius, respectively.
    3 context sentences
    Summary · context
    After teriparatide, 26 enrolled in the phase 2B denosumab extension (60 mg q6M) for 24 months.
    Summary · context
    Of 41 women enrolled in the parent teriparatide study (20 mcg daily), 34 enrolled in the HR-pQCT study.
    Summary · context
    HR-pQCT participants initially received teriparatide (N = 24) or placebo (N = 10) for 6 months; all then received teriparatide for 24 months.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.